Last reviewed · How we verify
Sequential use of P1101 and P1801 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Sequential use of P1101 and P1801 (Sequential use of P1101 and P1801) — PharmaEssentia.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sequential use of P1101 and P1801 TARGET | Sequential use of P1101 and P1801 | PharmaEssentia | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sequential use of P1101 and P1801 CI watch — RSS
- Sequential use of P1101 and P1801 CI watch — Atom
- Sequential use of P1101 and P1801 CI watch — JSON
- Sequential use of P1101 and P1801 alone — RSS
Cite this brief
Drug Landscape (2026). Sequential use of P1101 and P1801 — Competitive Intelligence Brief. https://druglandscape.com/ci/sequential-use-of-p1101-and-p1801. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab